By providing clinicians with information about the drug efficacy, the response and the relapse risk of the patient, they can get ready for treatment decision-making, understand the impact of adverse reaction, devise plans to optimize the use of therapeutic resources and benefit at-risk patients - all while enabling a favorable treatment outcome.

OncoMRD works across tumor, microenvironment and immune interaction domains, employing patient-unique gene signatures from multi-spectral biomarkers to provide detection, identification, quantification and tracking against a wide range of signals directly or indirectly from tumors.

OncoMRD is built on a panel of overactive genes. Gene expression profiling can be measured by qPCR or dPCR. The system employs crucial biomarkers in major cancer pathways, such as DNA repair, cell surface markers, transcription factors, tumorigenesis among others. Data from all biomarkers are collected and processed by digital analytics, which normalizes and calculates a OncoMRD score, based upon counts of the detected biomarkers, gene expression levels and the relevance weight of these biomarkers.

In addition to determining MRD, the OncoMRD score also has a valuable trending function. Gene expression data from the panel provides tracks in the system, which can be displayed in the report. These tracks can be used for monitoring in the disease follow-up role.

Additionally, the expression data from the OncoMRD gene panel is of very high quality, so that the system can be used for the gathering information of tumor activity or aggressiveness.

The invention of OncoMRD represents a new generation of MRD testing capability, which is equipped with functional genomics and joining the OncoDxRx exclusive technology bubble, alongside the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) and biomarker testing (or companion diagnostics) platform.